Actinium Pharmaceuticals, Inc.
ATNM- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001388320
No open-market purchases or sales by Actinium Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $5.18M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Actinium Pharmaceuticals, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 63 | 1 | 61 | −1 |
| Shares | 5.48M | 14.5K | 5.15M | −314.6K (−5.8%) |
| Value | $7.66M | $20.3K | $8.23M | +$589.9K (+7.7%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (9)
Institutions that held Actinium Pharmaceuticals, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Advisers, LP | 196,376 | $314.2K | 0.00% |
| Gen-Wealth Partners Inc | 109,381 | $175.0K | 0.06% |
| Mayport, LLC | 22,000 | $35.2K | 0.01% |
| Cetera Investment Advisers | 14,491 | $23.2K | 0.00% |
| Level Four Advisory Services, LLC | 10,000 | $16.0K | 0.00% |
| Rockefeller Capital Management L.P. | 4,500 | $7.20K | 0.00% |
| Advisory Services Network, LLC | 2,460 | $3.94K | 0.00% |
| Groupe la Francaise | 316 | $436 | 0.00% |
| SRS Capital Advisors, Inc. | 34 | $54 | 0.00% |
Sold out (10)
Institutions that held Actinium Pharmaceuticals, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Creative Financial Designs Inc | 109,381 | $153.1K |
| Goldman Sachs Group Inc | 91,411 | $128.0K |
| Y-Intercept (Hong Kong) Ltd | 64,909 | $90.9K |
| Jain Global LLC | 30,903 | $43.3K |
| Am Investment Strategies LLC | 30,872 | $43.0K |
| HRT Financial LP | 27,476 | $38.0K |
| Catalyst Funds Management Pty Ltd | 14,500 | $20.3K |
| Schonfeld Strategic Advisors LLC | 10,823 | $15.2K |
| Raymond James Financial Inc | 1,165 | $1.63K |
| Clearstead Advisors, LLC | 306 | $429 |
Not filed for Q3 2025 yet (1)
Institutions that held Actinium Pharmaceuticals, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Avantax Advisory Services, Inc. | 14,491 | $20.3K |